What is an opportunity?

SourceGenerics showcases opportunities ranging from technology and product dossiers through to portfolios and businesses. And to make your life easier, SourceGenerics focuses on generics products - no more, no less. So whether you want to in-license, out-license, buy or sell opportunities, advertise your services or target the right people, then SourceGenerics is the solution.

Each business opportunity is expected to result in a separate business deal. If you want to strike more than one deal, then you should post a separate opportunity for each potential deal.


Opportunities in these segments

  • Oral Solid-Dose Products
  • Topical Products
  • Injectable Products
  • Other Finished-Dosage Forms
  • Active Pharmaceutical Ingredients (APIs)
  • Intermediates

Types of opportunities

  • Products
  • Ingredients
  • Technology
  • Intellectual Property
  • Businesses
  • Dossiers
  • Patents
  • Distribution Rights


Einar Geir Hreinsson, Vice-President Strategic Projects at Actavis, says:
"We used this channel to reach potential customers and it turned out to be considerably more effective than we had expected. It is invaluable to be able to introduce a new project like Opening Pharma in this way, through a single portal with connections in all directions. This will be our first choice the next time we want to give a new project a good promotion."

Rich DiCicco, Chief Executive Officer of Harvest Moon Pharma, comments:
"Harvest Moon Pharma has listed its complex generics and biosimilars on SourceGenerics for three years. We have received enquiries from 206 companies - including Pfizer, Sanofi, Teva, Stada, Ranbaxy and Sandoz - from 58 countries, and we are very pleased with the results. We intend to keep listing on SourceGenerics indefinitely."

Sanjiv Puri, Chief Executive Officer of Australia's Generic Partners, tells us:
"Within a week of posting our business opportunities on SourceGenerics we had received over 10 quality enquiries from leading generics companies throughout the world."